Can Obama Help Vete...
Health Care: Drugs
AstraZeneca PLC (AZN: NYSE)
$40.08 -0.33 | -0.82%
06/01/12 - 04:01 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 40.08 |
| 52 Week High | 52.47 |
| 52 Week Low | 39.73 |
| Avg. Daily Vol. (Mil) | 1.64 |
| Beta (3 year) | 0.41 |
| Share Related Items | |
| Mkt Cap (Mil) | 51,059.15 |
| Shares Out (Mil) | 1,273.93 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 9.70 |
| Annual Dividend | 3.90 |
| Payout Ratio | 43.00 |
| Financial Strength | |
| Quick Ratio | 1.20 |
| Current Ratio | 1.40 |
| LT Debt/ Equity | 0.37 |
| Total Debt / Equity | 0.46 |
| Valuation Ratios | |
| Price Earnings | 6.20 |
| Price/Sales | 1.56 |
| Price/Book | 2.37 |
| Price/Cash Flow | 4.50 |
| Per Share Data | |
| Earnings | 6.51 |
| Sales | 25.63 |
| Book Value | 16.89 |
| Cash Flow | 8.82 |
| Business Summary | |
|---|---|
| AstraZeneca PLC a biopharmaceutical company focusing on six Therapy Areas: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology and Respiratory & Inflammation. It owns and operates R&D, production and marketing facilities worldwide. | |
| General Information | |
| 2 Kingdom Street
London, W2 6BD |
|
| 1.0 | |
| www.astrazeneca.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 57200 | |
| CEO: Mr David R Brennan | |
| Short Interest | |
| Current Month (Mil) | 3.00 |
| Previous Month (Mil) | 3.91 |
| Short Interest Ratio (Days) | 1.80 |
| Management Effectiveness | |
| Return on Equity | 40.50 |
| Return on Assets | 17.20 |
| Return on Investments | 29.70 |
| Profitability | |
| Gross Margin | 89.20 |
| EBIT Margin | 37.10 |
| Profit Margin | 26.70 |
Portfolios with AZN
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 14
- UserThe Coming M&A boom
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Dividend Stocks Still Pa...
- User2012 performers
- Contributor6 European Stocks Resistant...
- UserMoney Maker
- Userkeithj
- ContributorRocket Stocks for the Week ...
- ProJohn Hussman
Latest AZN Headlines from TheStreet
- 9 High-Yield Stocks to Consider in Lieu of Bonds 06.01.12 | 01:06 pm
- AstraZeneca PLC (AZN): Today's Featured Health Care Winner 05.03.12 | 05:05 pm
- The Next Big Thing in Biotech: M&A
04.27.12 | 05:04 am - AstraZeneca PLC (AZN): Today's Featured Drugs Loser 04.26.12 | 05:04 pm
- Rupert Murdoch in Second Day of Testimony: Hot Trends 04.26.12 | 08:04 am
- 14 Deal-Ready Stocks for the M&A Boom 04.26.12 | 06:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26 Billion: Hot Trends 04.23.12 | 10:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26B: Hot Trends 04.23.12 | 08:04 am
- AstraZeneca Wins Patent Protection on Seroquel: Hot Trends 03.30.12 | 10:03 am
- Stocks to Watch: Research In Motion, Dunkin' Brands (Update 1) 03.30.12 | 08:03 am
Press Releases for AZN
- Data Presented At The European Atherosclerosis Society Congress Reinforces The Differentiating Benefits Of CRESTOR[TM] In Comparison To Atorvastatin And Simvastatin - PR Newswire 05.28.12 | 01:05 am
- SYMBICORT® (budesonide/formoterol Fumarate Dihydrate) Long-Term Study Shows Similar Safety Profile When Compared To Budesonide Monotherapy In African-American Patients With Asthma - Business Wire 05.10.12 | 09:05 am
- LUNAR Examines Cholesterol-Lowering Effects Of CRESTOR® (rosuvastatin Calcium) Compared With Atorvastatin In Patients With Acute Coronary Syndrome - Business Wire 05.01.12 | 09:05 am
- AstraZeneca And The Medicines Company Announce Global Collaboration In Acute Ischemic Heart Disease - Business Wire 04.25.12 | 12:04 pm
- AstraZeneca Launches DUTOPROL™ (metoprolol Succinate Extended Release/hydrochlorothiazide) Tablets For High Blood Pressure In U.S. - Business Wire 04.12.12 | 09:04 am
- US District Court Finds SEROQUEL XR Formulation Patent Valid And Infringed - Business Wire 03.29.12 | 05:03 pm
- Crestor Delivers Latest LDL-C Targets In High-Risk Patients At Lower Doses Than Other Statins - PR Newswire 03.26.12 | 01:03 pm
- US Court Denies Preliminary Injunction Application Against The FDA And Dismisses AstraZeneca’s Lawsuit Without Prejudice - Business Wire 03.26.12 | 02:03 am
- New Data Suggests Results Of PLATO Genetic Sub-Study Outcomes For BRILINTA® (Ticagrelor) Not Driven By Poor Metabolizers Of Clopidogrel - Business Wire 03.25.12 | 11:03 am
- New Data Suggests BRILINTA® (ticagrelor) Reduced First And Recurrent Cardiovascular And Ischemic Events - Business Wire 03.25.12 | 11:03 am
Partner Headlines for AZN
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Analyst Insights: Finish Line, BioMarin Pharma, Laboratory Corp, Ocz Technology, AstraZeneca May 31st - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- 6 FTSE100 6%+ Dividend Yielders - Seeking Alpha 05.20.12 | 08:05 am
- Merger Arbitrage Mondays - May 14, 2012 - Seeking Alpha 05.14.12 | 09:05 am
- 4 New Reasons To Be Bullish On Sanofi Now - Seeking Alpha 05.13.12 | 09:05 am
- This Developmental Pharma Has Potential To Be A Long Term Multibagger - Seeking Alpha 05.03.12 | 09:05 am
- Spectrum: Increased Fusilev Production May Boost Stock - Seeking Alpha 04.30.12 | 09:04 am
- Benzinga's M&A Chatter for Friday April 27, 2012 - Benzinga 04.28.12 | 08:04 pm
- Earnings Recap for April 26, 2012 - Benzinga 04.26.12 | 09:04 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
